our everyone XXXX and you, call. quarter Thank third conference Good thanks for morning joining Mike.
objectives for we been we the with that a progress We key set several accomplished productive has across have of XXXX. in IMARA the what as year business and made continued
IMR-XXX with Xb disease. Ardent the of Importantly, then followed first patients in clinical milestone cell sickle we Xb that We dosed Forte beta-thalassemia October. in Phase in dosed the our trial with our patient Phase in in of first patient trial August IMR-XXX clinical
In has multiple in addition the support footprint conduct regulatory We countries these further centers as patients of activating as Xb to goals. Phase progress multiple enrollment approval important to expand anticipate our in these team dosing global well receiving clinical in these these efforts our to trials, all trials. patient studies made will
sickle to progress of continued also open as IMR-XXX trial ongoing Xa our well adult patients as OLE have trials sickle in extension Phase label We cell with disease. including trial clinical cell our of with adult our disease patients or
Phase These in are the Regarding help the completed of we topline dosing data from the Xa, patient this steps this review this of quarter fourth and data year. trial track on study. to end report us during third from this keep study toward finalizing quarter
open a or safety Our longer of which trial a label in Difficulty] will IMR-XXX. trial is and study OLE have enroll [Technical four-year to tolerability
During trial. quarter our key what believe conference the two call, aspects of we reported on we our second
We seen reported on now that OLE First and XX enrolled are the to XXX trend X continued. have increased second that today that pleased our we we receiving conference enrollment report reported of patients has had IMR-XXX. from patients All quarter up mg call. I'm we during
Difficulty] patients important at present presented mark. to plan that first ASH plan at we and We patients also believe [Technical two intervals December. in Meeting from we six-month the noted data that regarding what data that to these crossed on the had Annual data OLE be patients approximately two analyze additional to We
two XXXX We treatment. months the approximately reported OLE previously patients third six XX also that of XX anticipate of in from quarter beyond patients will we to report Difficulty] the [Technical data progress patients including
Commission front Disease Track and granted during made of Fast been also progress designation Drug, the important sickle Orphan designations disease. for cell Rare the for regulatory with Disease patients sickle treatment previously IMR-XXX European the cell IMR-XXX granted disease. third Orphan had as Pediatric on We from of the the treatment FDA quarter the
Difficulty]. we continue IMR-XXX differentiate from help Difficulty] beta and further the we of the began quarter outcomes cell the that addition, previously In XXXX. beyond in treatment Designation development are therapies third the at therapies granted [Technical designations rare disease believe also earlier as the thalassemia sickle IMR-XXX pediatric in development. having approved [Technical FDA during quarter patients of thalassemia diseases. Orphan XXXX beta for in these It clinical status In looking and We still of these designations Disease third of important in could
the risk in help ability cardiovascular cardiologists, disease. cell began IMR-XXX reduce exploring with of potential patients we to well-known its Specifically sickle with and
NT-proBNP from to baseline. who of As the Difficulty] plus well compared risk. at impact part mean data of a Briefly, hydroxyurea those XXst higher an baseline NT-proBNP, conducted as reduction effort exploratory while Conference of plus of IMR-XXX saw on mean mean marker hydroxyurea a patients clinical treated Sickle on values IMR-XXX by the increase alone. or interim from to Furthermore, greater XXth among level with were mean alone XX decrease Vanderbilt presented the patient was in a Medical [Technical HU Center Xa results our of established virtually NT-proBNP XXXX. baseline received [Technical in Cell and on University with held that a XX.X% a issue Thalassemia analysis increase saw who of baseline in in NT-proBNP NT-proBNP ASCAT and patients avascular of Patients IMR-XXX received October XX% XX.X% of Phase Difficulty] XXX Annual than from with showed pg/mL XX%
of the in IMR can a PDEX conducting and The the peptide preliminary prevention our studies, as biomarker implemented studies suggests resulting disease, cardiac for failure, Xb are we and treatment serve HFpEF. part target As and with to on including heart Phase GMP an are specifically treated when attractive XXX also modulation have these of preclinical [indiscernible] as presentation in data NT-proBNP Ardent further inhibition cyclic studies. literature help we increases ASCAT changes explore contained of cardiovascular [Technical models in patients Forte through natural of from risk Difficulty]
We this attenuates our the hypertrophy, are manner. dependent model confidence in that IMR-XXX cardiac from showed In work. treatment a indication of a phenotype recapitulates [indiscernible] and HFpEF that dose recent reduces gaining cardiac in preclinical we inflammation decreases
they cell to IMR-XXX. patients which showed months with Lastly IMR-XXX XXX like IMR-XXX with between a cardiovascular we for proof dose-dependent increase now a day mg dose efforts patients the believe in disease disease. fetal with developed clinical in June. hemoglobin fetal statistically started levels, of link disease, are cells where the at be a monotherapy disease of virtual In at would escalated containing red interim further EHA adult future for modifying sickle from to that Xa for XXX sickle our spend presented per three Congress significant mg and Beginning were oral studies three I results higher cells HFpEF [indiscernible] that NT-proBNP the few sickle as blood an as the trial as cell core cell per results. improvement day provides treatment sickle this financial an examined there could months. the day Phase programs minutes in our with on biomarkers like details increase cell the well hemoglobin cohort, of we potential once a important with that be and we concepts to in dose believe IMR-XXX data
at studies We to Patient administration enrollment Xa in earlier, Phase periods. the in now trial. the dose placebo from these the of second the of we six [Technical our in trials XXXX during trials can additional patients months. study from Patient randomized As sub patient during currently efforts patients our initiating several for mg of on X XXXX. patients of receiving mark XXX months. HU potential trial, the randomized quality intervals Difficulty] the and on as these data to to for enters of two month look was conference data potential we the of who OLE first patient presented originally reported combination this enrolled from during treatment Difficulty]. We the the to data on clinical XXX this Phase of approximately with they this in in trials never patients and duration Ardent facility trials OLE of in sub in these patient dose well updating on Difficulty] indicated in for respect stable that dose the year of I use plan this was to in data quarter to [Technical trial open X future of encouraging this extension vaso-occlusive the topline respect IMR-XXX year turn with study are and the potential data dose disease [Technical in this and group would label fourth X X beta-thalassemia. HU XXX patients, study at mentioned monotherapy Xb with analyze benefits had XXXX, as mg/XXX August expended We X the We call. Phase from are longer patients OLE six begun Patients have over which report biomarkers. the transit pleased Forte our trial Patients both for quarter patients. recent dosing the as all group crises completed expect mark including like Phase regards or Data XX and are dose. VOCs patient and to six-month patients completed last a IMR-XXX of completing XXXX. with both continue one IMR-XXX this view Phase Phase to clinical life quarter IMR-XXX study of and same substantial trials forward HU therefore the and year I from one the June disease months also to of IMR to as healthcare cell patients mg these patient from benefits sickle data We If at the with increase with of have to on late pleased in indicated in patients treatment effects of were these few the enroll VOCs of Xa trial.
global as trial the in sites expand the will disease who Phase of with double-blind, In number randomized well cell addition, by operate. is the sites we increase by region. have clinical will sickle enroll these as stratified HU a to Briefly, XX which will use patients Xb footprint trial, active and for of patients and Ardent continued be
weight dose top Ardent will The in trial measures The mg the Forte the [Technical to maximize adult associate dependent beta-thalassemia. our XXX on VOCs Recall mg. the approximately evaluate week-XX Patients endpoints, placebo Xb [Technical of to tolerability was for transfusion evaluation Xa red evaluate continue trial will on to planned of and is tests hemolysis, objective higher based and efficacy Phase non quality from approximately safety patients. NT-proBNP. provide XX utilizing across greater data doses Difficulty] and [Technical XXX [Technical this or Difficulty] indices statistical for are XX and blood primary of including dependent The exposure baseline cells dosing Phase secondary patients Difficulty] the is Difficulty] the white XXX up IMR-XXX of to and And in proportion We XX transfusion and versus trial life additional versus IMR-XXX patients to cell powered IMR-XXX. the weeks HbF biomarkers with of of [ph] placebo. additions, significance deterioration endpoint. and X% is trial for that with
as Like be of examine as a potential weeks Additionally, XX safety to and the on as weight assessed endpoints, initiation. endpoints. Ardent prior recorded we during and comparison the burden doses plan tolerability and XX The our of based in trial in IMR-XXX in to result to weeks placebo plan trial iron change exploratory to efficacy will study also we well evaluate XXX transfusion with after versus of effect will for high dependent dosing transfusion as as continue utilizing PK the transfusion Forte additional patients dosing. Safety load and rates mg. the
with Due report report we data analysis from timeline trials enrollment Forte estimated second treatment. plan adjusting expected have and interim to diligently COVID-XX time our with trial are completed XXXX much XXXX. to [Technical of first respectively formal the our as working as sites a as of possible. of to we the to our and Xb XX internally on clinical of XX delays XX interim Difficulty] minimize to half half delays well as reminder, patients As in the these CRO previously weeks
of reach Ardent centers we of the increase XX active and the example, continue Forte to global For countries. with clinical multiple studies
three [Technical countries final For approval have countries Difficulty] the centers with the and active beta-thalassemia XX active received have Forte planned clinical of clinical in XX we Ardent this in with countries, later nine study trial have centers regulatory five seven approval month. we expected sickle-cell in disease in
initiating age months in our ascending And to weight, more clinical this I results. In ahead to promising third half plan Imara enable for generally periods Oral and we third younger our in in dose due each believe We financial XXXX, scaling approximately COVID-XX. the program we now despite in progress preferred a Most progress. program, clinical We are centers first review clinical turn the program back children. other continuing We timeline the our preclinical anticipate you. pediatric to quarter of briefly oral previous be will patients, other expand IMR-XXX, and able in and we up on disease I mark of adolescents includes of based to to [Technical accelerate single planned been these customized have to touch study next. studies and our initiate forwards for to will program younger the multiple activate countries multiple party formulation dose sickle-cell currently six trial Difficulty] to stability across advancements primarily the productive Thank and data multiple extension solutions our of quarter in summary, third a solution on originally look manufacturing. which conduct dosing expectations. call Mike development to are notably, and and parameters.
